Biomarkers in Scleroderma: Progressing from Association to Clinical Utility

Area of Science:

• Rheumatology and Immunology
• Translational Medicine
• Biomarker Discovery

Background:

• Scleroderma is a complex autoimmune disease featuring vasculopathy and organ fibrosis.
• Understanding scleroderma's evolution is crucial for patient risk stratification and therapeutic development.
• Traditional single-marker approaches are being replaced by comprehensive molecular profiling.

Purpose of the Study:

• To review recent advancements in scleroderma biomarkers.
• To highlight biomarkers with prognostic value and potential for guiding management.
• To discuss novel approaches for characterizing disease extent and evolution.

Main Methods:

• Review of high-throughput technologies identifying fibrotic and inflammatory effectors.
• Analysis of circulating protein signatures and tissue gene expression patterns.
• Classification of patients into disease subtypes based on shared evolutionary patterns.

Main Results:

• Identification of fibrotic and inflammatory effectors with strong prognostic ability.
• Shift towards multi-marker investigations using protein and gene expression data.
• Development of methods for classifying patients into latent disease subtypes.

Conclusions:

• Biomarker discovery in scleroderma is expanding beyond traditional measures.
• Novel biomarkers and subtype classifications can improve risk prognostication and management.
• These advances are poised to guide prospective treatment strategies and serve as surrogate outcomes.